From a logistical standpoint it makes sense the Chinese would want our technology to treat their diabetes epidemic. They need a technology which can be transported, lasts a long time and is simplistic in application (doesn't require any devices to activate).
This bodes well for us shareholders because our patented technology can be cryo-preserved for at least five years (lending itself to worldwide transport) and can also be inside the human body for up to two years, maybe longer, without any immunosuppresive drugs (bioinert). Additionally, our technology requires just one simple injection - no devices or pumps necessary for activation.
Our Cell-in-a-Box®/Melligen cell combo effectively 'cures' both Type 1 and insulin-dependent Type 2 diabetes. This is exactly what the Chinese need.
Will J&J or CITIC be the buyer? It's beginning to look more and more like CITIC.
News 
Market Data 
Discover 
AI
